google_counter
background_img

Prostate Cancer Treatment with Lutetium-177 PSMA (program ID: 408538)

University Hospital Saarland Homburg

location_on Homburg, Germany
9.8/10 from 28 Votes
Specialized hospital
Samer Ezziddin

Head Physician
Prof. Dr. med.

Samer Ezziddin

Specialized in: nuclear medicine

Department of Nuclear Medicine

The Department of Nuclear Medicine annually provides treatment to more than 620 patients with metastatic prostate cancer. During the therapy a high-quality radioactive lutetium isotope (Lu-177) preparation is used. Lu-177 specifically bounds to the PSMA-containing tumor cells and metastases and kills them. Doctors of the department under the guidance of Prof. Dr. med. S. Ezziddin offer effective treatment with a minimal complications rate.

The program includes:

  • Initial presentation in the clinic
  • history taking
  • general clinical examination
  • laboratory tests:
    • complete blood count
    • biochemical analysis of blood
    • urinalysis
    • TSH-basal, fT3, fT4
    • PSA blood test
    • tests for urogenital infections
    • indicators of inflammation
    • indicators of blood coagulation
  • ultrasound scan of the urogenital system
  • renal scintigraphy
  • PSMA PET-CT (if indicated)
  • PSMA treatment
  • full body scintigraphy after 24 hours
  • full body scintigraphy after 48 hours
  • symptomatic treatment
  • cost of essential medicines
  • nursing services
  • elaboration of further recommendations
  • stay in the hospital with full board 
  • accommodation in a room with 2 beds

How program is carried out

During the first visit, the doctor will carry out a general physical examination and go through the results of your previous laboratory and instrumental tests. After that, you will undergo any necessary additional tests, such as an assessment of your liver and kidney function, a scintigraphy of your skeleton and salivary glands, a PSMA PET/CT. This will allow the doctor to assess how effective PSMA therapy with Lutetium-177 will be for you, and how well you will tolerate it. The doctor will also calculate your individual dosage of the radionuclide.

PSMA therapy with Lutetium-177 is carried out via intravenous administration of a solution containing the radioactive isotope, Lutetium-177. The solution is injected through a catheter. This is a short procedure, as the infusion usually takes no more than 20 minutes.

During the procedure, you will need to apply cooling bags to your salivary glands, as Lutetium-177 partially accumulates in the salivary glands, affecting their function and causing a dry mouth. You will also receive intravenous saline solutions to protect your kidneys.

After the infusion of Lutetium-177, you will stay in a specially equipped (radiation-shielded) ward for 48 hours. The drug is quickly excreted by the kidneys, and after 48 hours you will no longer be dangerous to others. During these 48 hours, you can read, use a mobile phone, tablet or computer – none of these devices will be a source of radiation in the future.

Follow-up examinations include either a whole-body scintigraphy or a computed tomography in 24 hours, and then again 48 hours after the procedure. Based on the results of this examination, the doctor will determine whether one procedure is enough for you, or whether you will need to visit the hospital again. As a rule, 1-2 procedures are required for achieving a stable, positive result. Procedures are carried out with an interval of 8 weeks.

Required documents:

  • Medical records
  • MRI/CT scan (not older than 3 months)
  • Biopsy results (if available)
Service
Price:
Type of program :
Expected duration of the program:

You may also book:

Price:

About the department

The Department of Nuclear Medicine at the University Hospital Saarland Homburg offers patients the full range of modern diagnostic and treatment methods in the field of nuclear medicine. The department is known as the largest medical facility of its kind in the South-West Germany. Treatment of thyroid diseases and oncological pathologies belongs to the main priorities of the department. The department is led by Prof. Dr. med. Samer Ezziddin.

Prof. Dr. Samer Ezziddin is an international expert in the treatment of neuroendocrine tumors and targeted radionuclide therapy. He also specializes in radioembolization, thyroid diagnostics and multimodal imaging with the use of PET-CT and SPECT-CT.

The examination to detect oncological diseases involves the use of PET diagnostics, which, if necessary, can be conducted with the participation of specialists in internal medicine, surgical oncology and radiation therapy. Another important examination is the diagnosis of sentinel lymph nodes, which has been conducted for many years on the basis of the Department of Dermatology for melanoma treatment, as well as on the basis of the Breast Center for the diagnosis of sentinel lymph nodes in mammary gland diseases.

Along with the diagnostics, the department also deals with treatment. It uses radioactive drugs that accumulate in the affected organ and provide targeted treatment without harming the rest of the body. Other treatment options include, for example, radioimmunotherapy in lymphomas, pain therapy in skeletal metastases, as well as selective internal radiation therapy for liver metastases.

Thanks to the competent and responsible attitude of the department's specialists, the dose of radiation, in most cases, is minimal, since there are used only small amounts of radioactive substances that quickly decay and can be eliminated from the body. Therefore, with virtually all methods of nuclear medicine, there are no side effects.

The diagnostic range of the department:

  • FDG-PET scan
  • PSMA PET/CT
  • PET/CT to detect amyloid protein (for example, in Alzheimer's disease)
  • FET PET-CT in brain tumors
  • PET/CT to identify somatostatin receptors
  • FDOPA PET/CT
  • Sodium Fluoride PET/CT
  • Choline PET/CT
  • And other diagnostic options

The therapeutic range of services includes the following options:

  • Radioiodine therapy
  • Radiosynoviorthesis (RSO)
  • Radio-phosphorous therapy for bone metastases
  • Selective internal radiation therapy
  • Radioimmunotherapy
  • Peptide receptor targeted radiation therapy
  • Therapy for bone metastases
  • Targeted radionuclide PSMA-therapy with Lu-177 isotope in metastatic prostate cancer
  • Targeted radionuclide PSMA-therapy with Ac-225 isotope in metastatic and recurrent prostate cancer
  • And other therapeutic options

Curriculum vitae

Higher Education and Professional Career

  • Human Medicine studies at the Goethe University Frankfurt.
  • 1997 German and American State Examinations.
  • 1998 Internship in Endocrinology and Hepatology at the University Hospital Cologne.
  • Board certification in Nuclear Medicine, Department of Nuclear Medicine at the University Hospital Bonn.
  • 2006 Senior Physician, Department of Nuclear Medicine at the University Hospital Bonn.
  • 2008 Managing Physician and Deputy Head of the Department of Nuclear Medicine at the University Hospital Bonn.
  • Completion of the part-time Master's program "Clinical medical technology" at the Rheinische Friedrich-Wilhelms University in Bonn.
  • 2014 Invitation to the position of Head of the Department of Nuclear Medicine at the University Hospital Saarland Homburg.
  • Professorship in Nuclear Medicine at the Saarland University.

Photo of the doctor: (c) Universitätsklinikum des Saarlandes


About hospital

Accommodation in hospital

There are 46 prostate cancer treatment hospitals on Booking Health website

Show all clinics

Certificates

Need Help?

Thank you!

We received your treatment application in the best Europe clinics. Our manager will contact you within the next 24 hours.